Literature DB >> 14663280

Elevated serum interleukin-15 level in acute graft-versus-host disease after hematopoietic cell transplantation.

Ki-wai Chik1, Karen Li, Henry Pong, Matthew Ming-kong Shing, Chi-Kong Li, Patrick Man-pan Yuen.   

Abstract

OBJECTIVE: To correlate serum cytokine levels and the development of acute graft-versus-host disease (GVHD), the authors conducted a prospective study on serial measurements of interferon (IFN)-gamma and interleukin (IL)-10, IL-12 and IL-15.
METHODS: The cytokines were measured in 27 subjects by enzyme-linked immunosorbent assay serially for the first 2 months after hematopoietic cell transplantation.
RESULTS: Nineteen subjects with acute GVHD had significantly higher mean peak serum levels of IFN-gamma and IL-15 than the baseline levels at the start of conditioning. The peak level occurred soon after stem cell infusion and returned to the pretransplantation state in the second month. In contrast, there was lesser difference between the mean peak serum levels of IFN-gamma, IL-10, and IL-15 and the baseline level in the eight subjects without GVHD. The peak serum level for IL-15 was, in addition, significantly higher among GVHD subjects than those without GVHD in the first month posttransplantation. However, the level of IL-15 showed no correlation with the severity of GVHD.
CONCLUSIONS: These changes point to a possible role of systemic cytokine secretion in the development of acute GVHD. Elevated levels of IL-15 early in the posttransplant period could be a helpful laboratory predictor of acute GVHD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14663280     DOI: 10.1097/00043426-200312000-00011

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  7 in total

1.  Expansion of a restricted residual host T reg-cell repertoire is dependent on IL-2 following experimental autologous hematopoietic stem transplantation.

Authors:  Allison L Bayer; Jackeline Chirinos; Cecilia Cabello; Jing Yang; Takaji Matsutani; Thomas R Malek; Robert B Levy
Journal:  Eur J Immunol       Date:  2011-10-31       Impact factor: 5.532

2.  Therapeutic activity of multiple common γ-chain cytokine inhibition in acute and chronic GVHD.

Authors:  Anne-Kathrin Hechinger; Benjamin A H Smith; Ryan Flynn; Kathrin Hanke; Cameron McDonald-Hyman; Patricia A Taylor; Dietmar Pfeifer; Björn Hackanson; Franziska Leonhardt; Gabriele Prinz; Heide Dierbach; Annette Schmitt-Graeff; Jiri Kovarik; Bruce R Blazar; Robert Zeiser
Journal:  Blood       Date:  2014-10-28       Impact factor: 22.113

3.  Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy.

Authors:  Maud Condomines; Jean-Luc Veyrune; Marion Larroque; Philippe Quittet; Pascal Latry; Cécile Lugagne; Catherine Hertogh; Tarik Kanouni; Jean-François Rossi; Bernard Klein
Journal:  J Immunol       Date:  2009-12-04       Impact factor: 5.422

Review 4.  T cell immune reconstitution following lymphodepletion.

Authors:  Kirsten M Williams; Frances T Hakim; Ronald E Gress
Journal:  Semin Immunol       Date:  2007-11-19       Impact factor: 11.130

Review 5.  Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation.

Authors:  Kirsten M Williams; Ronald E Gress
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

6.  Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors.

Authors:  Miroslaw J Szczepanski; Marta Szajnik; Ann Welsh; Kenneth A Foon; Theresa L Whiteside; Michael Boyiadzis
Journal:  Cancer Immunol Immunother       Date:  2009-06-13       Impact factor: 6.968

7.  Kinetics of T helper subsets and associated cytokines correlate well with the clinical activity of graft-versus-host disease.

Authors:  Su-Peng Yeh; Yu-Min Liao; Wen-Jyi Lo; Chiao-Lin Lin; Li-Yuan Bai; Chen-Yuan Lin; Ching-Yun Hsieh; Yu-Chien Chang; Yu-Ting Huang; Chang-Fang Chiu
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.